ReviewPharmaceutics2022
Nanotechnology in the Diagnosis and Treatment of Osteomyelitis.
Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Identification of genetically-supported new drug targets for osteomyelitis based on druggable genomes.Human genomics · 2025Pooled it
- Liposomal multimodal theranostics for bone disorders: from rational responsive delivery and biomimetic strategies to clinical translation.Journal of nanobiotechnology · 2026Review
- Immunomodulatory Biomaterials for Bone and Soft Tissue Chronic Inflammation Diseases.Small science · 2025Review
- Nature Is a Valuable Source for the Biosynthesis of Nanoparticles and Their Effects on the Treatment of Osteomyelitis.Journal of cellular and molecular medicine · 2025Review
- Multiscale metal-based nanocomposites for bone and joint disease therapies.Materials today. Bio · 2025Review
- A comprehensive review of pathology and treatment of staphylococcus aureus osteomyelitis.Clinical and experimental medicine · 2025Review
- Novel antimicrobial strategies for diabetic foot infections: addressing challenges and resistance.Acta diabetologica · 2025Review
- Metal Nanoparticles: From Endophytic Fungi-Mediated Biosynthesis to Their Therapeutic Applications in Oncology.International journal of nanomedicine · 2025Review
- Influence of Altered Immune-Inflammatory Axis on the Risk of Osteomyelitis and Its Network Interaction Effect in European Population.Mediators of inflammation · 2025Article
- Dual function ofFrontiers in microbiology · 2025Article
- Nanomaterial-mediated antibiotic delivery: a novel strategy for osteomyelitis therapy.Frontiers in bioengineering and biotechnology · 2025Review
- Nano-scaffold-based delivery systems of antimicrobial agents in the treatment of osteomyelitis ; a narrative review.Heliyon · 2024Review
- Development of Hybrid Implantable Local Release Systems Based on PLGA Nanoparticles with Applications in Bone Diseases.Polymers · 2024Article
- Enhanced Antibacterial Efficacy of Bioceramic Implants Functionalized with Ciprofloxacin: An In Silico and In Vitro Study.Pharmaceutics · 2024Article
- Current research progress of local drug delivery systems based on biodegradable polymers in treating chronic osteomyelitis.Frontiers in bioengineering and biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infection remains one of the largest threats to global health. Among those infections that are especially troublesome, osteomyelitis, or inflammation of the bone, typically due to infection, is a particularly difficult condition to diagnose and treat. This difficulty stems not only from the biological complexities of opportunistic infections designed to avoid the onslaught of both the host immune system as well as exogenous antibiotics, but also from changes in the host vasculature and the heterogeneity of infectious presentations. While several groups have attempted to classify and stage osteomyelitis, controversy remains, often delaying diagnosis and treatment. Despite a host of preclinical treatment advances being incubated in academic and company research and development labs worldwide, clinical treatment strategies remain relatively stagnant, including surgical debridement and lengthy courses of intravenous antibiotics, both of which may compromise the overall health of the bone and the patient. This manuscript reviews the current methods for diagnosing and treating osteomyelitis and then contemplates the role that nanotechnology might play in the advancement of osteomyelitis treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.